Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALMS, AMLX, ABVX, PCVX, PHVS, and represent 49.49% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CADL (+$14M), IRON (+$9.7M), IMMX (+$6.3M), ZURA, IVVD, OVID, XFOR, ANRO, MSLE, PHVS.
- Started 4 new stock positions in CADL, MSLE, ANRO, ZURA.
- Reduced shares in these 9 stocks: COGT (-$23M), OCUL (-$18M), JAZZ (-$16M), DYN (-$15M), ABVX (-$12M), Centessa Pharmaceuticals (-$7.1M), CELC, AMLX, IVA.
- Sold out of its positions in Centessa Pharmaceuticals, IVA, OCUL.
- Saturn V Capital Management was a net seller of stock by $-43M.
- Saturn V Capital Management has $552M in assets under management (AUM), dropping by 1.34%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 21 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alumis (ALMS) | 12.8 | $71M | +2% | 3.2M | 22.03 |
|
| Amylyx Pharmaceuticals (AMLX) | 10.9 | $61M | -3% | 4.3M | 13.90 |
|
| Abivax Sa Sponsored Ads (ABVX) | 10.9 | $60M | -16% | 543k | 111.35 |
|
| Vaxcyte (PCVX) | 8.7 | $48M | +3% | 825k | 58.11 |
|
| Pharvaris N V (PHVS) | 6.1 | $34M | +5% | 1.2M | 28.25 |
|
| Immix Biopharma (IMMX) | 6.1 | $34M | +23% | 3.7M | 9.11 |
|
| Celcuity (CELC) | 5.8 | $32M | -11% | 282k | 114.14 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 5.6 | $31M | -34% | 163k | 189.05 |
|
| Disc Medicine (IRON) | 5.2 | $29M | +50% | 450k | 63.94 |
|
| X4 Pharmaceuticals Com New (XFOR) | 4.8 | $27M | +11% | 6.5M | 4.13 |
|
| Cogent Biosciences (COGT) | 4.4 | $24M | -48% | 627k | 38.49 |
|
| Monopar Therapeutics Com New (MNPR) | 3.4 | $19M | +6% | 346k | 54.79 |
|
| Dyne Therapeutics (DYN) | 3.2 | $18M | -45% | 967k | 18.13 |
|
| Adagio Therapeutics (IVVD) | 2.6 | $14M | +41% | 11M | 1.30 |
|
| Candel Therapeutics (CADL) | 2.6 | $14M | NEW | 2.9M | 4.90 |
|
| Oculis Holding Ordinary Shares (OCS) | 2.5 | $14M | 517k | 26.59 |
|
|
| Ovid Therapeutics (OVID) | 1.7 | $9.2M | +66% | 4.2M | 2.22 |
|
| Inhibikase Therapeutics Com New (IKT) | 1.2 | $6.5M | 3.9M | 1.68 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.8 | $4.4M | NEW | 740k | 5.95 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.4 | $2.0M | NEW | 89k | 22.48 |
|
| Satellos Bioscience (MSLE) | 0.4 | $2.0M | NEW | 350k | 5.63 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2026 Q1 filed May 15, 2026
- Saturn V Capital Management 2025 Q4 filed Feb. 17, 2026
- Saturn V Capital Management 2025 Q3 filed Nov. 14, 2025
- Saturn V Capital Management 2025 Q2 filed Aug. 13, 2025
- Saturn V Capital Management 2025 Q1 filed May 15, 2025
- Saturn V Capital Management 2024 Q4 filed Feb. 14, 2025
- Saturn V Capital Management 2024 Q3 filed Nov. 14, 2024
- Saturn V Capital Management 2024 Q2 filed Aug. 14, 2024
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023